Table 5.

Associations between dplotypes of CASP3 promoter polymorphisms and progression of SCCHN^*

Stratified variables*	CASP3 diplotype		Crude OR	Adjusted OR†	P‡
	n (case/control)	Two copies of TCG or GCA
Primary tumor (T)
T1	221/993	34.4/27.0	1.42 (1.04-1.94)	1.40 (1.01-1.92)	0.027
T2	327/993	33.0/27.0	1.33 (1.02-1.75)	1.30 (0.98-1.71)	0.036
T3	196/993	30.1/27.0	1.17 (0.83-1.63)	1.14 (0.81-1.61)	0.372
T4	186/993	33.3/27.0	1.35 (0.97-1.89)	1.28 (0.89-1.83)	0.078
Lymph node metastasis
N0	343/993	33.5/27.0	1.37 (1.05-1.78)	1.35 (1.02-1.78)	0.021
N1	135/993	30.4/27.0	1.18 (0.80-1.75)	1.10 (0.74-1.65)	0.409
N2	415/993	33.0/27.0	1.33 (1.04-1.71)	1.33 (1.03-1.72)	0.023
N3	37/993	32.4/27.0	1.30 (0.64-2.62)	1.25 (0.61-2.56)	0.465
Combine T and N
T1,2 and N0	352/993	34.9/27.0	1.45 (1.12-1.89)	1.45 (1.11-1.89)	0.005
T3,4 or N1-3	578/993	31.5/27.0	1.24 (0.99-1.56)	1.22 (0.96-1.54)	0.057

Note: The result is bolded if the 95% confidence interval does not include 1 or P < 0.05.

^*Stratified variables: T: The extent of the primary SCCHN. T₁: tumor ≤ 2 cm at the greatest dimension; T₂ to T₄: increasing greatest dimensions. N: regional lymph node involvement. N₀: no regional lymph nodes involved; N₁ to N₃: increasing involvement of regional lymph nodes.

^†Adjusted OR: odds ratios were adjusted for age, gender, smoking status, and alcohol use.

^‡P value from the χ² test of different frequencies of CASP3 genotypes in cases and controls.